title: A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain.
abstract: This study evaluated the impact of treatment with Buprenorphine Transdermal System (BTDS) on the health-related quality of life for patients with moderate-to-severe chronic low back pain (CLBP), and the correspondence between quality of life and pain. A multicenter, enriched, double-blind (DB), placebo-controlled, randomized trial evaluated BTDS 10 and 20 μg/hour for treatment of opioid-naïve patients with moderate-to-severe CLBP. The SF-36v2 survey, which measures 8 domains of quality of life, was administered at screening and following an open-label run-in period with BTDS and at weeks 4, 8, and 12 of the DB phase. Post hoc analyses compared SF-36v2 scores between BTDS and placebo groups during the DB phase. Condition burden was examined through comparisons with a U.S. general population sample. Correlations examined the correspondence between quality of life and pain measures. BTDS produced larger improvements than placebo at 12 weeks in all quality-of-life domains (Ps < .05). Treatment group differences in both physical and mental quality of life emerged by 4 weeks. Patients' pretreatment quality of life was worse than that in the general population (Ps < .05); only BTDS treatment eliminated deficits in pain, social functioning, and role limitations due to emotional health. Improvements in quality of life were moderately associated with pain reduction. These data suggest that moderate-to-severe CLBP patients receiving BTDS exhibited better quality of life than patients receiving placebo.
  
  
  CONCLUSIONS
  This post hoc analysis suggests that patients with moderate-to-severe CLBP treated with BTDS exhibit better health-related quality of life than those using placebo within 4 weeks of treatment, and were more likely to exhibit clinically meaningful improvements in quality of life following 12 weeks of treatment.
authors.affiliation: QualityMetric Inc, Lincoln, Rhode Island 02865, USA. ayarlas@qualitymetric.com
authors.forename: Aaron
authors.initials: A
authors.lastname: Yarlas
authors.forename: Kate
authors.initials: K
authors.lastname: Miller
authors.forename: Warren
authors.initials: W
authors.lastname: Wen
authors.forename: Bradley
authors.initials: B
authors.lastname: Dain
authors.forename: Shau Yu
authors.initials: SY
authors.lastname: Lynch
authors.forename: Joseph V
authors.initials: JV
authors.lastname: Pergolizzi
authors.forename: Robert B
authors.initials: RB
authors.lastname: Raffa
authors.forename: Steven R
authors.initials: SR
authors.lastname: Ripa
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000627:therapeutic use*; D002047:Buprenorphine / Q000008:administration & dosage / Q000627:therapeutic use*; D017281:Cost of Illness; D004311:Double-Blind Method; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D017116:Low Back Pain / Q000188:drug therapy* / Q000523:psychology*; D008297:Male; D009043:Motor Activity; D010147:Pain Measurement; D011788:Quality of Life
chemical_list: D000701:Analgesics, Opioid; D002047:Buprenorphine